For example, aberrant DDR activation has been linked to resistance in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), with FLT3-ITD and Bcr-Abl mutations conferring resistance to tyrosine kinase inhibitors (TKIs) such as imatinib (Huang and Zhou, 2021). The gene discussed is FLT3; the disease is acute myeloid leukemia.